First Physician Office System Using a Fluorescent Biomarker to Reveal Biological Activity Invisible to the Naked Eye

LOS GATOS, CA, April 3, 2018 — Orlucent, Inc., a privately held medical device company, today announced its Orlucent® system obtained CE Marking for noninvasive evaluation of moles suspicious for melanoma. The easy to use 3-part system yields rapid results in the physician office. The ORLUCENT topical biomarker, handheld imager, and software work in tandem to provide the physician with biological activity status from within a suspect mole prior to a decision to biopsy. The CE (Conformité Européenne, or “European Conformity”) Marking declares conformity that the product meets European safety, effectiveness, and quality requirements. The Orlucent system is supported by studies in over 500 patients. Additional clinical trials are underway in both the US and Europe.